NCT05698537Completed
Risk Factors and Etiologies of Epilepsy in Urban and Rural Rwanda
Source: ClinicalTrials.gov · Last updated 20 Jun 2024
Brief summary (registry, in English)
Epilepsy is one of the most common chronic brain disorders. Up to 85% of persons living with epilepsy (PwE) live in the developing world. In sub-Saharan Africa (SSA), Rwanda has one of the highest prevalence rates (±5%). Higher prevalence in low-and middle-income countries (LMICs) can partly be attributed to differences in risk factors for epilepsy of which a great number are preventable. Expanding knowledge on risk factors and etiologies of epilepsy in Rwanda can lower the portion of preventable epilepsies and decrease the high number of Rwandan PwE. This project will focus on the investigation of risk factors and etiologies of epilepsy in urban and rural Rwanda using a nationwide approach.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1745 (actual)
- First submitted
- 4 Jan 2023
- Start date
- 31 May 2022
- Primary completion date
- 24 May 2024
- Lead sponsor
- University Hospital, Ghent
- Diseases
- Epilepsy
- NCT number
- NCT05698537
What you commit to
- Study type: Observational
- Participants enrolled: 1745
- From 31 May 2022 to the primary completion date, 24 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Inhabitants of the selected villages who are unwilling to complete a verbal witnessed informed consent during D2D visits. For patients ≤18 years of age, verbal consent will be obtained from their parents/caregivers.
Other
- PwE and selected control persons who are unwilling to sign a written informed consent upon referral for neurological assessment.
- PwE and control persons not meeting the inclusion criteria.
Who the study is looking for
- Inhabitants of the selected villages who screen positive on the Limoges epilepsy screening questionnaire during the D2D visits and have a confirmed epilepsy diagnosis assessed by a team of Rwandan and Belgian neurologists, are included as PwE. Epilepsy will be defined as unprovoked recurrent seizures occurring more than 24h apart, including active and lifetime epilepsy.
- Persons with a negative screening during the D2D visits who match with a PwE for age and gender and have an absence of epilepsy confirmed during a clinical assessment by a team of Rwandan and Belgian neurologists, are included as control persons.
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| King Faisal Hospital Coordinator of this site? Confirm its status | Kigali | Rwanda | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.